ReviewNeuropsychiatric disease and treatment2018
Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy.
Review in Neuropsychiatric disease and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Clinical Utility of Cariprazine in the Management of Acute Schizophrenia: Current Evidence and Practical Recommendations.Actas espanolas de psiquiatria · 2026Review
- Cariprazine as a candidate for drug repurposing in anorexia nervosa: a mechanistic hypothesis grounded in neuroimaging evidence.Frontiers in pharmacology · 2026Article
- Cariprazine and clozapine combination for the treatment of psychosis in a young, female patient with schizophrenia: a case report.Frontiers in psychiatry · 2024Article
- A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia.Frontiers in psychiatry · 2024Review
- Therapeutic Appropriateness of Cariprazine in the Management of Schizophrenia: Experts' Opinion using a Delphi Approach.Current neuropharmacology · 2023Article
- Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents.Tremor and other hyperkinetic movements (New York, N.Y.) · 2022Review
- Case Report: Long-Acting Oral Cariprazine.Frontiers in psychiatry · 2022Article
- Using Cariprazine to Ameliorate Negative Symptoms and Metabolic Side Effects of Clozapine and Paliperidone - Clinical Cases.Neuropsychiatric disease and treatment · 2022Article
- Cariprazine on Psychosis: Beyond Schizophrenia - A Case Series.Neuropsychiatric disease and treatment · 2022Article
- Case Report: Functional and Symptomatic Improvement With Cariprazine in Various Psychiatric Patients: A Case Series.Frontiers in psychiatry · 2022Article
- Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?World journal of psychiatry · 2021Review
- Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs-Influence of Smoking Behavior and Inflammation on Pharmacokinetics.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Cariprazine Use in Early Psychosis: Three Case Reports.Frontiers in psychiatry · 2021Article
- Case Report: Severe Side Effects Following Treatment With First Generation Antipsychotics While Cariprazine Leads to Full Recovery.Frontiers in psychiatry · 2021Article
- Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study).Frontiers in psychiatry · 2021Article
- Asenapine: an atypical antipsychotic with atypical formulations.Therapeutic advances in psychopharmacology · 2021Review
- Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data.Therapeutic advances in psychopharmacology · 2020Review
- Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm.Neuropsychiatric disease and treatment · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cariprazine is an oral antipsychotic approved in the US and EU for the treatment of schizophrenia. Cariprazine differs from other antipsychotics in that it is a dopamine D
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.